The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 04, 2014

Filed:

Nov. 08, 2006
Applicants:

Lili Feng, Pine Brook, NJ (US);

Sven Erik Godtfredsen, Chatham, NJ (US);

Bin HU, Green Brook, NJ (US);

Yugang Liu, Bridgewater, NJ (US);

Piotr Karpinski, Lincoln Park, NJ (US);

Paul Allen Sutton, Parsippany, NJ (US);

Mahavir Prashad, Montville, NJ (US);

Michael J. Girgis, Montville, NJ (US);

Thomas J. Blacklock, Clark, NJ (US);

Inventors:

Lili Feng, Pine Brook, NJ (US);

Sven Erik Godtfredsen, Chatham, NJ (US);

Bin Hu, Green Brook, NJ (US);

Yugang Liu, Bridgewater, NJ (US);

Piotr Karpinski, Lincoln Park, NJ (US);

Paul Allen Sutton, Parsippany, NJ (US);

Mahavir Prashad, Montville, NJ (US);

Michael J. Girgis, Montville, NJ (US);

Thomas J. Blacklock, Clark, NJ (US);

Assignee:

Novartis Pharmaceuticals Corporation, East Hanover, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 257/04 (2006.01); C07C 233/47 (2006.01); A61K 31/41 (2006.01); A61K 31/4422 (2006.01); A61K 31/5415 (2006.01);
U.S. Cl.
CPC ...
C07D 257/04 (2013.01); C07C 233/47 (2013.01); A61K 2300/00 (2013.01); A61K 31/4422 (2013.01); A61K 31/5415 (2013.01); A61K 31/41 (2013.01);
Abstract

A compound of an angiotensin receptor antagonist (ARB), a neutral endopeptidase inhibitor (NEPi) and one or more monovalent cations are useful for the treatment of hypertension and/or heart failure. ARB includes S—N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine in the anion form, NEPi includes (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in the anion form and cation includes monovalent cations such as Na. The compound includes trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate] hemipentahydrate.


Find Patent Forward Citations

Loading…